Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis

被引:33
作者
Dai, ZH [1 ]
Kerzic, P [1 ]
Schroeder, WG [1 ]
McNiece, IK [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Expt Hematol Lab, Denver, CO 80262 USA
关键词
D O I
10.1074/jbc.M101170200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hematopoietic cells from patients with Ber-Abl-positive chronic myelogenous leukemia exhibit multiple abnormalities of cytoskeletal function. The molecular events leading to these abnormalities are not fully understood. Previously we showed that Bcr-Abl elicits ubiquitin-dependent degradation of Abl. interactor proteins. Because recent studies have suggested a role of Abl interactor proteins in the pathway that regulates cytoskeletal function, we investigated whether mutations in Ber-Abl that interfere with the signaling to Abl interactor proteins affect its leukemogenic activity. We report here that the Src homology 3 domain and C-terminal proline-rich sequences of Bcr-Abl are required for its binding to Abl interactor 2 as well as for the induction of Abl interactor 2 degradation. Although the deletion of these regions did not affect the ability of the mutant Bcr-Abl to transform hematopoietic cells to growth factor independence, it abrogated its ability to stimulate spontaneous cell migration on fibronectin-coated surfaces. Furthermore, the mutant Bcr-Abl, defective in binding to Abl interactor 2 and inducing its degradation, failed to induce chronic myelogenous leukemia-like disease in mouse. These results are consistent with a role of Abl interactor proteins in the regulation of cytoskeletal function as well as in the pathogenesis of Bcr-Abl-induced leukemogenesis.
引用
收藏
页码:28954 / 28960
页数:7
相关论文
共 42 条
[11]   Abl interactor 1 binds to Sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases [J].
Fan, PD ;
Goff, SP .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (20) :7591-7601
[12]  
Gotoh A, 1997, Curr Opin Hematol, V4, P3
[13]  
Gross AW, 1999, MOL CELL BIOL, V19, P6918
[14]   Rho GTPases and the actin cytoskeleton [J].
Hall, A .
SCIENCE, 1998, 279 (5350) :509-514
[15]  
HARLOW E, 1999, USING ANTIBODIES LAB, P74
[16]   Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation [J].
Heaney, C ;
Kolibaba, K ;
Bhat, A ;
Oda, T ;
Ohno, S ;
Fanning, S ;
Druker, BJ .
BLOOD, 1997, 89 (01) :297-306
[17]   ACUTE-LEUKEMIA IN BCR/ABL TRANSGENIC MICE [J].
HEISTERKAMP, N ;
JENSTER, G ;
TENHOEVE, J ;
ZOVICH, D ;
PATTENGALE, PK ;
GROFFEN, J .
NATURE, 1990, 344 (6263) :251-253
[18]   Reversibility of acute B-cell leukaemia induced by BCR-ABL1 [J].
Huettner, CS ;
Zhang, P ;
Van Etten, RA ;
Tenen, DG .
NATURE GENETICS, 2000, 24 (01) :57-60
[19]   Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K [J].
Keely, PJ ;
Westwick, JK ;
Whitehead, IP ;
Der, CJ ;
Parise, LV .
NATURE, 1997, 390 (6660) :632-636
[20]   The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity [J].
Li, SG ;
Ilaria, RL ;
Million, RP ;
Daley, GQ ;
Van Etten, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (09) :1399-1412